Billiontoone (NASDAQ:BLLN) Stock Price Down 4.6% - Here's What Happened

Key Points

• Billiontoone shares fell 4.6% to $112.72 in mid-day trading, with volume down 86% from the average session. The stock has a $5.24 billion market capitalization and trades at a price-to-earnings ratio of 158.46.
• Analyst sentiment is mixed: seven analysts rate the stock Buy, two Hold, and two Sell, resulting in a consensus Hold rating and an average price target of $125.88. Guggenheim initiated coverage with a $125 target, while BTIG and JPMorgan lowered their targets to $130.
• The company met quarterly earnings expectations with EPS of $0.15 and revenue of $109.45 million. However, insiders sold 244,108 shares worth approximately $28 million over the last quarter, including sales by the CTO and a senior vice president under pre-arranged trading plans.

Billiontoone, Inc. (NASDAQ:BLLN - Get Free Report) traded down 4.6% during mid-day trading on Wednesday. The company traded as low as $112.75 and last traded at $112.72. Approximately 74,648 shares were traded during mid-day trading, a decline of 86% from the average session volume of 548,232 shares. The stock had previously closed at $118.18.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on BLLN shares. Weiss Ratings reissued a "sell (d+)" rating on shares of Billiontoone in a report on Friday, September 18th. Guggenheim initiated coverage on Billiontoone in a research note on Monday, June 29th. They issued a "buy" rating and a $125.00 target price for the company. BTIG Research lowered their price target on Billiontoone from $142.00 to $130.00 and set a "buy" rating for the company in a research report on Thursday, August 6th. Wall Street Zen downgraded Billiontoone from a "buy" rating to a "hold" rating in a research note on Saturday, August 8th. Finally, JPMorgan Chase & Co. cut their price objective on Billiontoone from $145.00 to $130.00 and set an "overweight" rating on the stock in a report on Thursday, August 6th. Seven analysts have rated the stock with a Buy rating, two have given a Hold rating and two have given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $125.88.

Billiontoone Price Performance

The stock has a market cap of $5.24 billion and a price-to-earnings ratio of 158.46. The stock's 50 day moving average price is $108.37 and its two-hundred day moving average price is $99.23. The company has a quick ratio of 11.31, a current ratio of 11.69 and a debt-to-equity ratio of 0.17.

Billiontoone (NASDAQ:BLLN - Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported $0.15 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.15. Billiontoone had a net margin of 8.04% and a return on equity of 9.96%. The company had revenue of $109.45 million during the quarter. Equities research analysts forecast that Billiontoone, Inc. will post 0.83 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CTO David Tsao sold 3,333 shares of the firm's stock in a transaction dated Thursday, September 24th. The stock was sold at an average price of $125.00, for a total transaction of $416,625.00. Following the sale, the chief technology officer directly owned 1,000 shares in the company, valued at $125,000. This trade represents a 76.92% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Bosch John Roderick Ten sold 1,416 shares of the firm's stock in a transaction that occurred on Thursday, September 24th. The shares were sold at an average price of $120.00, for a total value of $169,920.00. Following the completion of the sale, the senior vice president directly owned 22,219 shares in the company, valued at approximately $2,666,280. The trade was a 5.99% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 244,108 shares of company stock worth $27,991,574. 50.22% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Billiontoone

A number of large investors have recently added to or reduced their stakes in BLLN. Integrated Wealth Concepts LLC purchased a new position in Billiontoone during the second quarter valued at $29,000. MCF Advisors LLC increased its stake in shares of Billiontoone by 330.8% during the second quarter. MCF Advisors LLC now owns 448 shares of the company's stock worth $54,000 after purchasing an additional 344 shares in the last quarter. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Billiontoone during the fourth quarter worth about $230,000. Thrive Wealth Management LLC acquired a new position in shares of Billiontoone during the 2nd quarter worth about $240,000. Finally, Jasper Ridge Partners L.P. acquired a new position in shares of Billiontoone during the 2nd quarter worth about $615,000.

About Billiontoone

BillionToOne, Inc is a molecular diagnostics company that develops blood-based tests designed to provide genetic and health information from small amounts of biological material. The company's technology uses its proprietary quantitative counting template approach to improve the accuracy and sensitivity of molecular testing.

The company's primary offerings include UNITY, a portfolio of prenatal genetic tests. These services support screening for chromosomal conditions, single-gene disorders and carrier status, and are designed to help healthcare providers assess fetal and maternal genetic risks using a maternal blood sample.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.